Vivien Bramwell

8.2k total citations · 3 hit papers
75 papers, 5.1k citations indexed

About

Vivien Bramwell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Vivien Bramwell has authored 75 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 16 papers in Rheumatology. Recurrent topics in Vivien Bramwell's work include Sarcoma Diagnosis and Treatment (36 papers), Vascular Tumors and Angiosarcomas (20 papers) and Breast Cancer Treatment Studies (14 papers). Vivien Bramwell is often cited by papers focused on Sarcoma Diagnosis and Treatment (36 papers), Vascular Tumors and Angiosarcomas (20 papers) and Breast Cancer Treatment Studies (14 papers). Vivien Bramwell collaborates with scholars based in Canada, United Kingdom and United States. Vivien Bramwell's co-authors include Lois E. Shepherd, Kathleen I. Pritchard, Ann F. Chambers, Dongsheng Tu, Mark N. Levine, George D. Demetri, Christopher W. Ryan, Ernest C. Borden, Margaret von Mehren and Cathryn Rankin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Vivien Bramwell

73 papers receiving 4.9k citations

Hit Papers

Phase III Randomized, Int... 2008 2026 2014 2020 2008 2008 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
    2008 768 citations Vivien Bramwell et al. profile →
  2. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
    2008 436 citations Vivien Bramwell et al. profile →
  3. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
    2012 383 citations Penella J. Woll, Pancras C.W. Hogendoorn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vivien Bramwell Canada 32 2.6k 2.4k 1.0k 953 942 75 5.1k
Ole S. Nielsen Denmark 38 3.5k 1.3× 2.2k 0.9× 1.2k 1.2× 711 0.7× 848 0.9× 117 6.0k
Elena Tamborini Italy 44 3.3k 1.3× 1.8k 0.7× 1.1k 1.1× 456 0.5× 1.1k 1.1× 144 5.6k
Scott H. Okuno United States 42 3.6k 1.4× 2.5k 1.0× 806 0.8× 461 0.5× 959 1.0× 178 5.8k
Philippe A. Cassier France 43 3.2k 1.2× 4.0k 1.6× 801 0.8× 1.1k 1.1× 1.4k 1.5× 295 7.4k
Martin E. Blackstein Canada 37 3.9k 1.5× 2.0k 0.8× 2.5k 2.4× 561 0.6× 1.0k 1.1× 101 6.3k
Jörg T. Hartmann Germany 31 2.7k 1.1× 3.4k 1.4× 593 0.6× 581 0.6× 762 0.8× 69 5.8k
Agnieszka Woźniak Belgium 38 3.4k 1.3× 1.6k 0.6× 2.0k 1.9× 546 0.6× 1.1k 1.1× 188 5.2k
A. van Oosterom Belgium 34 4.2k 1.6× 1.8k 0.8× 3.1k 2.9× 484 0.5× 861 0.9× 88 6.7k
Andrés Poveda Spain 39 2.2k 0.8× 2.3k 1.0× 681 0.6× 594 0.6× 909 1.0× 157 5.8k
John F. Gibbs United States 39 1.6k 0.6× 2.1k 0.9× 514 0.5× 555 0.6× 705 0.7× 150 4.7k

Countries citing papers authored by Vivien Bramwell

Since Specialization
Citations

This map shows the geographic impact of Vivien Bramwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivien Bramwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivien Bramwell more than expected).

Fields of papers citing papers by Vivien Bramwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivien Bramwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivien Bramwell. The network helps show where Vivien Bramwell may publish in the future.

Co-authorship network of co-authors of Vivien Bramwell

This figure shows the co-authorship network connecting the top 25 collaborators of Vivien Bramwell. A scholar is included among the top collaborators of Vivien Bramwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivien Bramwell. Vivien Bramwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asleh, Karama, Dongsheng Tu, Dongxia Gao, et al.. (2021). Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical Cancer Research. 27(23). 6570–6579. 2 indexed citations
2.
Buchanan, Marguerite, Olga Aleynikova, Dongsheng Tu, et al.. (2013). RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial. PLoS ONE. 8(12). e81740–e81740. 8 indexed citations
3.
Chia, Stephen, Vivien Bramwell, Dongsheng Tu, et al.. (2012). A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18(16). 4465–4472. 220 indexed citations
4.
5.
Gelderblom, Hans, Rachel C. Jinks, Matthew R. Sydes, et al.. (2011). Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. European Journal of Cancer. 47(6). 895–902. 104 indexed citations
6.
7.
Bramwell, Vivien, Gordon S. Doig, Alan B. Tuck, et al.. (2008). Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Research and Treatment. 114(3). 503–511. 41 indexed citations
8.
Pritchard, Kathleen I., Lois E. Shepherd, Frances P. O’Malley, et al.. (2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine. 354(20). 2103–2111. 372 indexed citations
9.
Morris, Don, Vivien Bramwell, Robert Turcotte, et al.. (2006). A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. Sarcoma. 2006(1). 64374–64374. 30 indexed citations
10.
Keith, Bruce & Vivien Bramwell. (2000). Pyomyositis After Chemotherapy for Breast Cancer. American Journal of Clinical Oncology. 23(1). 42–44. 9 indexed citations
11.
Bramwell, Vivien. (2000). Osteosarcomas and other cancers of bone. Current Opinion in Oncology. 12(4). 330–336. 38 indexed citations
12.
Saad, Zahida, Vivien Bramwell, Sylvia M. Wilson, et al.. (1998). Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. The Lancet. 351(9110). 1170–1173. 27 indexed citations
13.
Williams, Chris, Mark Lodge, & Vivien Bramwell. (1997). Cancer reviews need to be systematic if they are to be reliable. European Journal of Cancer. 33. S128–S129. 1 indexed citations
14.
O’Malley, Frances P., Zahida Saad, Nancy Kerkvliet, et al.. (1996). The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Human Pathology. 27(9). 955–963. 48 indexed citations
15.
Mertens, Wilson C., et al.. (1995). High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets. Cancer Immunology Immunotherapy. 41(5). 271–279. 1 indexed citations
16.
Levine, Mark N., Vivien Bramwell, Kathleen I. Pritchard, et al.. (1993). A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. 29(1). 37–43. 18 indexed citations
17.
Mertens, Wilson C., Vivien Bramwell, Peeyush K. Lala, et al.. (1992). Continuous Indomethacin and Ranitidine with Interleukin‐2 in Advanced Renal Carcinoma and Melanoma: A Preliminary Report. Canadian Journal of Infectious Diseases and Medical Microbiology. 3(B). 133–137. 1 indexed citations
18.
Bramwell, Vivien. (1988). Intraarterial chemotherapy of soft‐tissue sarcomas. Seminars in Surgical Oncology. 4(1). 66–72. 9 indexed citations
19.
Wong, Wai‐Man, V. R. Tindall, John Wagstaff, Vivien Bramwell, & Derek Crowther. (1985). Surgery and Radiotherapy in the Treatment of Primary Carcinoma of the Fallopian Tube – Report of 18 Cases. Australian and New Zealand Journal of Obstetrics and Gynaecology. 25(3). 211–215. 2 indexed citations
20.
Bramwell, Vivien, et al.. (1979). The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemotherapy and Pharmacology. 3(4). 253–9. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ole S. Nielsen Breakdown of academic impact, for papers by Elena Tamborini Breakdown of academic impact, for papers by Scott H. Okuno Breakdown of academic impact, for papers by Philippe A. Cassier Breakdown of academic impact, for papers by Martin E. Blackstein Breakdown of academic impact, for papers by Jörg T. Hartmann Breakdown of academic impact, for papers by Agnieszka Woźniak Breakdown of academic impact, for papers by A. van Oosterom Breakdown of academic impact, for papers by Andrés Poveda Breakdown of academic impact, for papers by John F. Gibbs
Rankless by CCL
2026